1. White matter hyperintensity shape is related to long-term progression of cerebrovascular disease in community-dwelling older adults.
- Author
-
Kuhn-Keller JA, Sigurdsson S, Launer LJ, van Buchem MA, van Osch MJ, Gudnason V, and de Bresser J
- Subjects
- Humans, Male, Female, Aged, Aged, 80 and over, Independent Living, Follow-Up Studies, White Matter diagnostic imaging, White Matter pathology, Disease Progression, Cerebrovascular Disorders diagnostic imaging, Cerebrovascular Disorders pathology, Magnetic Resonance Imaging
- Abstract
White matter hyperintensity (WMH) shape is associated with long-term dementia risk in community-dwelling older adults, however, the underlying structural correlates of this association are unknown. We therefore aimed to investigate the association between baseline WMH shape and cerebrovascular disease progression over time in community-dwelling older adults. The association of WMH shape and cerebrovascular disease markers was investigated using linear and logistic regression models in the Age, Gene/Environment Susceptibility-Reykjavik (AGES) study (n = 2297; average time to follow-up: 5.2 years). A more irregular shape of periventricular/confluent WMH at baseline was associated with a larger increase in WMH volume, and with occurrence of new subcortical infarcts, new microbleeds, new enlarged perivascular spaces, and new cerebellar infarcts at the 5.2-year follow-up (all p < 0.05). Furthermore, less elongated and more irregularly shaped deep WMHs were associated with a larger increase in WMH volume, and new cortical infarcts at follow-up (p < 0.05). A less elongated shape of deep WMH was associated with new microbleeds at follow-up (p < 0.05). Our findings show that WMH shape may be indicative of the type of cerebrovascular disease marker progression. This underlines the significance of WMH shape to aid in the assessment of cerebrovascular disease progression., Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.J.P. van Osch reports to be an unpaid member of a clinical trial steering committee of Alnylam.
- Published
- 2025
- Full Text
- View/download PDF